Klin Onkol 2015; 28(2): 134-138. DOI: 10.14735/amko2015134.
Summary
Nowadays, EGFR- TKIs (epidermal growth factor receptor- tyrosine kinase inhibitors) targeted therapy is well established treatment for patients with the so- called EGFR common mutations with advanced or metastatic non-small cell lung cancer. The efficacy for the so- called rare and especially for the very rare complex EGFR mutations is not clear. We describe a case of a 63- year-old female with metastatic non-small cell lung cancer with complex EGFR mutation (G719X + S768I) who had been treated by gefitinib. She achieved progression free survival within eight months. Then, we discuss our case with other literature case reports. Together, it seems that described complex EGFR mutation has a relatively good sensitivity for EGFR- TKIs treatment.
